Patents by Inventor Keith STEELE

Keith STEELE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240044901
    Abstract: The present invention relates to the field of prognostic of lung cancer. In this study, the inventors used extensive gene expression profiling and flow cytometry for an integrative analysis of the phenotypes of the B cells and CD4+ T cells from tumors and blood of NSCLC patients by TLS-B density. They showed that TIL B cells and TIL CD4+ T cells are more highly activated in tumors than in the periphery and that they express all the ligand/receptor pairs necessary for B/T interactions and two-way co-stimulation. Moreover, a high density of TLS-B cells is associated with higher frequencies of activated CD4+ T cells and lower frequencies of both immune checkpoint (ICP)-expressing CD4+ T cells and regulatory CD4+ T cells (Tregs) in the intratumor CD4+ T cell compartment. High densities of TLS-B cells together with low densities of FoxP3+ CD3+ Tregs in NSCLC tumors consistently identified the group of patients with the best clinical outcome.
    Type: Application
    Filed: February 8, 2022
    Publication date: February 8, 2024
    Inventors: Marie-Caroline DIEU-NOSJEAN, Claire GERMAIN, Scott Alan HAMMOND, Keith STEELE
  • Publication number: 20210171639
    Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 10, 2021
    Inventors: RAJESH NARWAL, DAVID FAIRMAN, PAUL ROBBINS, MEINA LIANG, AMY SCHNEIDER, CARLOS CHAVEZ, CARINA HERL, MIN PAK, HONG LU, MARLON REBELATTO, KEITH STEELE, ANMARIE BOUTRIN, LI SHI, SHENGYAN HONG, BRANDON HIGGS, LORIN ROSKOS
  • Publication number: 20190256603
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of durvalumab (MEDI4736) or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof. A combination of durvalumab and tremelimumab was effective at treating non-small cell lung cancers characterized as PD-L1- and having a high level of CD8+ tumor-infiltrating lymphocytes.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 22, 2019
    Inventors: KEITH STEELE, SONG WU, BRANDON HIGGS, MORITZ WIDMAIER, SONJA ALTHAMMER, RENE KORN, ANDREAS SPITZMUELLER
  • Publication number: 20180364240
    Abstract: Provided herein are methods of treating a tumor comprising administering an effective amount of one or more immune-mediated cancer therapies, including durvalumab (MEDI4736) or an antigen-binding fragment thereof. Analysis of tumor sample sections using image analysis and gene expression identified patients for which immune-mediated cancer therapy would be effective. Durvalumab was effective at treating non-small cell lung cancers characterized by image analysis using tumor cell and immune cell markers (e.g., PD-Lq1 and CD8) and gene expression (e.g. IFN#).
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Inventors: GERD BINNIG, SONJA ALTHAMMER, GUENTER SCHMIDT, BRANDON HIGGS, KEITH STEELE
  • Publication number: 20160031990
    Abstract: Provided herein are methods of treating HPV-negative tumors comprising administering an effective amount of an antagonist of the PDL-1/PD-1 interaction (e.g., an anti-PDL-1 or anti-PD-1 antibody antigen binding fragment thereof).
    Type: Application
    Filed: May 28, 2015
    Publication date: February 4, 2016
    Inventors: Keith STEELE, Marlon C. Rebelatto, John Andrew Blake-Haskins, Paul B. Robbins, James R. Vasselli, Ross A. Stewart, Ramy Ibrahim, Aiman Shalabi